ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 97 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,453 | -8.5% | 62,292 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $138,179 | -16.8% | 60,078 | +9.6% | 0.00% | 0.0% |
| Q1 2023 | $166,141 | +32.7% | 54,832 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $125,217 | +27.8% | 53,741 | +4.8% | 0.00% | 0.0% |
| Q3 2022 | $98,000 | -28.5% | 51,269 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $137,000 | +1.5% | 50,544 | +11.7% | 0.00% | 0.0% |
| Q1 2022 | $135,000 | -18.7% | 45,232 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $166,000 | -12.2% | 42,699 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $189,000 | +42.1% | 43,977 | +0.5% | 0.00% | – |
| Q2 2021 | $133,000 | +64.2% | 43,763 | +94.4% | 0.00% | – |
| Q1 2019 | $81,000 | -9.0% | 22,516 | -3.1% | 0.00% | – |
| Q4 2018 | $89,000 | -59.7% | 23,245 | -0.8% | 0.00% | -100.0% |
| Q3 2018 | $221,000 | +31.5% | 23,425 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $168,000 | – | 23,002 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Whitefort Capital Management, LP | 11,895,477 | $24,147,818 | 12.66% |
| Two Seas Capital LP | 8,280,818 | $16,810,061 | 3.38% |
| FourWorld Capital Management LLC | 1,341,907 | $2,724,071 | 0.51% |
| Tejara Capital Ltd | 180,077 | $365,556 | 0.21% |
| Woodline Partners LP | 4,719,903 | $9,581,403 | 0.11% |
| Hudson Bay Capital Management LP | 8,299,808 | $16,848,610 | 0.07% |
| Kepos Capital LP | 155,691 | $316 | 0.06% |
| Virtus ETF Advisers LLC | 40,040 | $81,281 | 0.05% |
| Centiva Capital, LP | 1,071,705 | $2,175,561 | 0.05% |
| Kades & Cheifetz LLC | 20,000 | $40,600 | 0.03% |